Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
SMART POINT-OF-CARE DEVICE FOR SELF-PATIENT MANAGEMENT OF THE ORAL ANTICOAGULANT THERAPY (CoaguPOC)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: SME instrument
Countries involved: Spain
Call: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-05-01
End date: 2017-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The goal we seek in CoaguPOC project is to develop a “ready to the market” smart point-of-care device for self-patient management of the Oral Anticoagulant Therapy (OAT). OAT is a long-term or even chronic therapy necessary to inhibit the formation of potentially lethal blood clots in patients with high risk of thrombosis; e.g. strokes, the 2nd single largest cause of death in the world. Approximately 2% of the population are prescribed long-term oral anticoagulants, meaning that more than 10-12 million people are treated in Western Europe. OAT therapy needs regular tests to confirm correct dosage levels because the drugs have a narrow therapeutic window and small changes in systemic changes can give rise to adverse toxic effects. Tests are usually made once a month in a nursing service at the hospital or care center. The constant increase on the number of anti-coagulant patients (around 10% annually) is highly intensifying pressure and cost on the healthcare resources required to monitor, prevent and manage adverse events. The use of point-of-care coagulometers at home for self-monitoring may avoid unnecessary visits to hospitals or clinics while permitting more frequent monitoring and timely adjustment of anticoagulant dosing to avoid adverse events. The OAT self-management leads to important reductions on adverse events, as thrombosis (reduction by 50%), major hemorrhages (12%), death (18%) and thrombotic events (67%) as compared to ‘usual care‘. It also has a substantial impact on the quality of life of patients and their families, and important cost savings on the healthcare system. For instance, in UK a mere increase of 5% improved in average therapeutic range, led to a reduction of 550 strokes per year and associated cost saving of around €12,000 per patient. CoaguPOC aims bringing to the market the first low-cost and smart point of care device for OAT patients to self-monitor and self-manage their chronic condition. We aim to bring the lab to your pocket

Keywords: coagulometer,anticoagulant,point of care,ehealth,stroke,thrombosis
Enhanced micropollutant oxidation by permanganate- and manganese(II)-based processes in presence of dissolved organic matter and hydrogen peroxide (Enhanced oxidation)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-06-01
End date: 2023-05-31
Duration (months): 24.0
Total project cost (EUR): 191149.44
EU funding (EUR): 191149.44
Participants: 1
Project status: SIGNED

Micropollutants are a serious problem for drinking water and wastewater due to their adverse human and ecosystem’s health effects. In Europe, their abatement often involves ozonation with O3 and hydroxyl radical abating a wide spectrum of micropollutants. However, the potential formation of carcinogenic disinfection byproducts such as bromate and N-nitrosamines threatens the safety of drinking water/wastewater. Permanganate (Mn(VII)) is a selective oxidant that is widely applied in pre-oxidation steps in water treatment to remove Mn(II), Fe(II) and taste/odor and produces little disinfection byproducts. It has a high reactivity with phenolic compounds. The applicant found that the phenolic moieties in dissolved organic matter (DOM) produce secondary oxidants with permanganate to enhance micropollutant abatement. Furthermore, the applicant discovered that hydrogen peroxide (H2O2) can not only produce secondary oxidants including Mn(VI) and superoxide radical when reacting with permanganate to enhance micropollutant abatement, but also reduce permanganate to MnO2 that can be removed during coagulation and filtration. Moreover, superoxide and hydroxyl radical were observed to be produced by the Mn(II)-H2O2 reaction. As another matrix, bicarbonate (HCO3–/CO32–) facilitated the Mn(II)-H2O2 reaction to achieve a fast micropollutant abatement, which shows a good application potential for reduced water sources by dosing H2O2. This project aims to investigate the kinetics and mechanisms of the enhancing role of DOM, its surrogate compounds and H2O2 on MnO4–-induced micropollutant abatement. Furthermore, the effectiveness of Mn(II)/H2O2(/HCO3–/CO32–) for micropollutant abatement will be investigated. Both processes will provide alternative enhanced oxidative treatment to abate micropollutants in water and wastewater.

Keywords: oxidation,enhancement,micropollutant,permanganate,manganese ii,dissolved organic matter,hydrogen peroxide
Feasibility study for an innovative “Regenerative Atmosphere Packaging” for fresh chicken (FRESHRAP)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: SME instrument
Countries involved: Spain
Call: Resource-efficient eco-innovative food production and processing (H2020-SMEINST-1-2015, 2015)
Start date: 2016-03-01
End date: 2016-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Packaging has improved the safety and quality of poultry products. Currently, MAP (Modified Atmosphere Packaging) is the most widely used packaging system. MAP seals fresh produce in a tray with a controlled atmosphere that contains gases that slow the degradation of the product. SCIENCEPACK has designed and developed an innovative “Regenerative Atmosphere Packing” (RAP) that offers an effective alternative to the conventional MAP system. The key to this innovation is that, thanks to a specific tray design and active coating (AC), CO2 is slowly released from the packaging. This allows the tray to regenerate the product preserving. FRESHRAP’s represents a huge opportunity for our company (SCIENCEPACK) to commercialise an innovative solution that will increase the shelf life, quality and the safety of fresh chicken parts. This offers us the opportunity to launch a new product on to the large and growing packaging tray market. FRESHRAP will promote the efficient use of resources and reduce food waste by extending 1-1.5 days the shelf-life of fresh chicken, and removing the need to dispose of opened, in-date chicken trays. 60% of Europeans throw away opened chicken meat, causing approximately 360,000 tonnes of waste per year in Europe. We offer the possibility to end this waste. FRESHRAP will also help to ensure that food remains safe to eat for longer, reducing the number of customers suffering from food contamination (Campylobacter). Finally, FRESHRAP will also support packaging companies by reducing the high capital and operational costs of MAP packaging. Initial market projections suggest that FRESHRAP will achieve sales of 5 million units in the first year of commercialisation, growing to 30 million by 2022, earning profits of over 2M€ and a ROI on project investment of 94%.

Keywords: food safety,regeneration co2,packaging,shelf life
Complete Automatization of Tissue Microarray Systems: Unleashing High-Throughput in Pathology Diagnosis, Prognosis and Anticancer Therapy (Prometeo)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Italy
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-11-01
End date: 2017-02-28
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Tissue microarray (TMA) is a practical and effective tool for molecular analysis of tissues that is helping identify new diagnostic and prognostic markers and targets in human cancers. In fact, the global microarray market is estimated to reach €6.7 billion by 2018. However, the manual steps of the TMA technique are a serious bottleneck as they are preventing high throughput analysis of multiple samples from multiple donors. Although many attempts have been done (confirming the market niche) to automatize TMAs, just few companies have products on the market which are more efficient that performing the technique manually. Unfortunately, these products use semi-automatic procedures which involve many tedious manual steps, and they are barely used by researchers. PROMETEO is a fully automated TMA system for routine clinical use in a high-throughput manner. It solves the bottleneck which is currently hindering diagnostic and research laboratories. Our project consist on improving and automatizing three devices: Tissue arrayer (sample slicer); Slide scanner; and the Whole Slide Image recognition algorithms. It benefits end users and society because the TMA technology will reduce diagnostic costs since over 400 patient samples can be analysed simultaneously, without additional workload, reducing tissue sample and reagent waste. Furthermore, it increases reproducibility of the results and creates a standard method. ISENET has the ingredients to be successful developing PROMETEO because, besides their highly qualified team, they have experience in designing and commercializing TMA equipment all over the world for 20 years. We have estimated that during the five years after commercialization starts, we will sell worldwide 91 full automated PROMETEO TMAs and 243 basic TMAs. For that purpose, we will hire 8 new technical employees. We will earn almost €12M cumulative profit, break even the second year, and generate a R.O.I of 6.97 by commercializing PROMETEO.

Keywords: automated tissue microarray,diagnostics,therapy,high throughput,automatic
New food for special medical purposes to nutritionally manage Myotonic Dystrophy type 1 (MYODM-FSMP)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-10-01
End date: 2021-06-30
Duration (months): 21.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Myotonic Dystrophy type 1 (DM1) is the most common and multisystemic neuromuscular rare disease affecting 1 million people worldwide, 100,000 EU citizens, who still have no cure or treatment available. In the light of the ´Leave No-one Behind´ commitment behind Sustainable Development Goals and particularly, the dietary management approach may provide a unique option for rare disease patients through Foods for special medical purposes (FSMP), foods (not drugs) intended for the dietary management of individuals who suffer from certain diseases. The main goal of the present project is to compile in human evidences that MYODM’s food for special medical purposes is a unique approach to improve DM1 patients’ Quality of Life through a pilot clinical trial for foods and supplements sponsored by Myogem and leaded by Dr. Adolfo López de Munain, a worldwide neurologist specialized in DM1. MYOGEM is the current licensee of the patents WO2016075288 A1 and WO2016075285 A1, which disclosed the effects of some methylxanthines on DM1. Owning the Intellectual Property Rights over the present solution is one of the main competitive advantages of MYOGEM. MYOGEM is the first and unique company worldwide who launched a food supplement for a rare disease in May 2017. However, as food supplement MYODM faces the problem that DM1 community, either neurologists and patient associations, claim for in human data in order to broadly prescribe and consume the product. To overcome this barrier, and gain market confidence, MYOGEM aims to perform a Feasibility pilot clinical trial to demonstrate MYODM’s effect on a small cohort of 10-15 DM1 patients in order to commercially upgrade our current product “food supplement” to “food for special medical purpose”, from now on referred as MYODM-FSMP, that will reach the market in less than one year after the present project ends. By launching the new MYODM-FSMP product, a 5.5 M€ SOM is expected in 5 years after the project. Two SoE have been awarded.
Naked mole-rats to mice: metabolic reprogramming to prevent ischaemic injury (METAMOLE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Germany
Call: ERC Starting Grant (ERC-2019-STG, 2019)
Start date: 2021-01-01
End date: 2025-12-31
Duration (months): 60.0
Total project cost (EUR): 1550000.0
EU funding (EUR): 1550000.0
Participants: 1
Project status: SIGNED

The overarching aim of this proposal is to identify unique features of naked mole-rat cardiac metabolism that serve as advantageous adaptations to deal with a hypoxic environment, a state relevant to heart disease. Coronary heart disease is a leading cause of death and its pathogenesis has been linked to metabolic abnormalities. The naked mole–rat has recently emerged as a rodent model of interest to biomedicine due to its extraordinarily long and healthy lifespan (>36 years). Naked mole-rats exhibit various atypical cardiac features including a remodelled metabolism that serve as adaptations to their extremely hypoxic and hypercapnic environment, and also contribute to the negligible decline in heart function with age. I will use “omics” technologies to examine the genetic, epigenetic and post-translational features underlying naked mole-rat rewired metabolism, hypoxia tolerance and myocardial fitness. I have shown that the naked mole-rat can survive extended periods under extreme hypoxia without apparent damage, by switching its metabolism to utilise fructose. Use of fructose in ischaemic conditions could therefore prove beneficial in other mammals. I will assess whether enhancing fructose metabolism via transgenic mouse models is protective under ischaemic conditions. I have shown that the transcriptional landscape of the naked mole-rat myocardium has preserved several neonatal-like features. Since neonatal mammalian heart has regenerative capacity, a quality that is quickly lost after birth, naked mole-rats may be the first adult mammalian model for heart regeneration. This project will measure regenerative capacity of the adult naked mole-rat heart and the mechanisms by which it may retain its proliferative competency. By introducing these features into the mouse I aim to validate and understand the benefit of these unique traits in promoting a healthy myocardium with possibilities for translating these discoveries into novel therapeutic strategies in man.

Keywords: metabolism,hypoxia,heart disease,metabolic reprogramming,regeneration,non standard organism
Defining the intrinsic transcriptional programs and the microenvironmental signals tailoring lung Interstitial Macrophage IDentity (IM-ID)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Immunity, Infection and Immunotherapy
Panel description: The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
Countries involved: Belgium
Call: ERC Starting Grant (ERC-2018-STG, 2018)
Start date: 2019-01-01
End date: 2024-12-31
Duration (months): 72.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

The mechanisms underlying lung homeostasis are of fundamental biological importance and have critical implications for the prevention of immune-mediated diseases such as asthma. We have demonstrated that lung Interstitial Macrophages (IM) exhibit a tolerogenic profile and are able to prevent and limit the development of aberrant immune responses against allergens, thus underscoring their role as crucial regulators of lung homeostasis. In addition, we have shown that IM could expand from monocyte precursors upon host exposure to bacterial unmethylated CpG-DNA, resulting in robust protection against allergic asthma. To date, however, IM have only been characterized as a bulk population in functional studies, and little is known about the tissue-instructive signals, specific transcription factors and differentiation programs which contribute to determining their identity (ID) and function, as proposed by the macrophage niche model. We have developed an innovative transgenic tool to selectively target IM which, in combination with high dimensional single cell technologies, will allow us to (1) define the precise ID of IM, i.e. their spatial organization, heterogeneity, molecular signature and the specific TF governing their differentiation and function; (2) investigate how IM ID is imprinted by the local niche to sustain lung homeostasis. Specifically, we aim to identify the epithelial cell-derived chemo-attractive signals controlling IM precursor recruitment and to elucidate the contribution of the lung cholinergic nervous system to IM ID and lung homeostasis. This research will increase our understanding of the basic mechanisms underlying the fine-tuning of tolerogenic IM and will thus provide robust foundations for novel IM-targeted approaches promoting health and preventing airway diseases in which IM (dys)functions have been implicated.

Keywords: lung immune homeostasis,macrophage niche,tissue imprinting,master transcription factor,neuroimmune and epithelial cell interactions,selective macrophage targeting,mouse models
Providing Verification Assistance for New Content (PROVENANCE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Countries involved: Austria,Ireland,Spain,Spain,Czechia
Call: Future Hyper-connected Sociality (H2020-ICT-2018-2, 2018)
Start date: 2018-12-01
End date: 2022-05-31
Duration (months): 42.0
Total project cost (EUR): 2696454.08
EU funding (EUR): 2438810.0
Participants: 8
Project status: CLOSED

PROVENANCE will develop an intermediary-free solution for digital content verification that gives greater control to users of social media and underpins the dynamics of social sharing in values of trust, openness, and fair participation. Specifically, PROVENANCE will use blockchain to record, in a secure and verifiable manner, multimedia content that is uploaded and registered by content creators or identified for registration by the PROVENANCE Social Network Monitor. The PROVENANCE Verification Layer will apply advanced tools for multimedia analytics (semantic uplift, image forensics, cascade analysis) to record any modifications to content assets and to identify similar pieces of content. A personalised Digital Companion will cater to the information needs of end-users. To help consumers navigate content and develop digital literacy competencies, an iconographic Verification Indicator will contextualise individual pieces of content with relevant information including when the content was registered, by whom, and any subsequent transactions. PROVENANCE will be co-created with diverse representatives of civil society across four distinct use-cases in the social media domain (citizen information seekers, citizen prosumers, factual content creators, and creative content creators). However, the findings will be applicable to any area in which social media and verification are important. The scientific and pragmatic insights gained through PROVENANCE will significantly advance the state of the art in intermediary-free solutions for content verification, understanding of information cascades and information sources on social media, the openness of algorithms, and user control over personal data. In so doing, it will lay the foundation for a new federated social network grounded in trust, openness, and fair participation. In addition, it will support the development of an observatory on information veracity and social media best practice under the ICT28 CSA.

Keywords: digital literacy,trust for social media,social media governance,citizen participation
Artificial Intelligent Dentistry for cost-efficient X-ray analysis and diagnosis (AID)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Netherlands
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-02-29
Duration (months): 3.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Promaton has built the first of its kind fully automated 2D and 3D X-ray analysis and diagnosis solutions. These Artificial Intelligent Dentistry (AID) solutions significantly reduce labour time and costs of dentists. They speed up tasks of dentist, such as X-ray data cleaning, annotation, segmentation, classification and detection of dental structures and diseases with 90%. Competitors’ offerings require annually on the average as much as 18 days of work or €29,000 in labour costs per dentist more. Promaton aims to penetrate first the French, Benelux and Southern Europe dental analysis and diagnosis markets before scaling up to the German and the American markets. It expects to achieve at least a 2% share of the €2b dental X-ray analysis and diagnosis market and to have grown to more than 200 employees by 2027. Thereto, it proposes large manufacturers to integrate its AID solutions with their own software and hardware platforms for dental X-ray analysis and diagnosis and license the AID solutions at €500 per year per client (being practice or dental clinic). In return, these manufacturers are allowed to white label, co-brand, and license the integrated AID solutions to their client base at their own convenient price points. Asking more than €1,000 per dental practice per year, Promaton’s competitors are expected to phase themselves out quickly. During the AID project, Promaton will validate its value proposition and business model (based on fixed or per analysis-diagnosis fee) with Benelux, French and Southern Europe strategic partners. It will benchmark competitive and alternative solutions, consulting renowned members from medical industry and science. It will consolidate the project results in a viable business plan for industrialization of its DL-based innovations. Meanwhile, it will also certify these innovations as medical software devices and file patents to protect their IPR.

Keywords: x ray scans,analysis,diagnosis